Filing Flows › NovoCure (NVCR) › Q2 2025
NovoCure (NVCR) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 24, 2025
NovoCure (NVCR) reported revenue of $159M for the second quarter 2025 (Q2 2025), +6% from a year earlier and +2% from the quarter before. Operating margin was -24.9%, net loss $40.1M (25.3% of revenue).
NovoCure, Q2 2025: revenue $159M (+6% year over year), operating margin -24.9%, net loss $40.1M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $159M | +2% | +6% |
| Operating profit | −$39.5M | — | — |
| Net earnings | −$40.1M | — | — |
| Operating cash flow | −$15.9M | — | — |
What changed
Revenue was $158.8M in Q2 2025, up 6% year over year and up 2% from the previous quarter.
Gross margin was 73.9%, down 3.1 points from a year earlier. Operating costs exceeded revenue by $39.5M, an operating margin of -24.9%. Operating expenses grew 5% against revenue growth of 6%. The fastest-growing cost line was General & admin (+17%). The quarter ended with a net loss of $40.1M, wider than the previous quarter's $34.3M loss.
Operating cash flow was −$15.9M. Non-cash charges added back $3.4M of depreciation and amortization and $26.1M of share-based compensation. Working capital and other items used $5.4M. Capital expenditures of $5.5M exceeded it, leaving free cash flow of −$21.4M.
Questions
What was NovoCure's revenue in the second quarter 2025?
NovoCure (NVCR) reported revenue of $159M for the second quarter 2025 (Q2 2025), +6% from a year earlier and +2% from the quarter before.
Was NovoCure profitable in the second quarter 2025?
Operating loss was $39.5M (-24.9% of revenue) and net loss $40.1M.
Source: NovoCure 10-Q on SEC EDGAR.